SEC Form 4 · accession 0000899243-18-025079
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Morningside Venture Investments Ltd
10% Owner
Period of report
Sep 20, 2018
Accepted (ET)
Sep 24, 2018 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4 | Sep 20, 2018 | P | 19,599 | $18.79 | A | 11,512,902 | D | |
| Common StockF2,F4 | Sep 20, 2018 | P | 21,724 | $19.43 | A | 11,534,626 | D | |
| Common StockF3,F4 | Sep 21, 2018 | P | 40,000 | $19.84 | A | 11,574,626 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $18.25 to $19.24, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $19.25 to $19.60, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price is a weighted average price. These shares were purchased on 9/21/2018 in multiple transactions at prices ranging from $19.48 to $20.14, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.